Biogen (NASDAQ: BIIB) reported a 12% increase in adjusted EPS and 2% growth in revenue for the second quarter of 2020. Adjusted EPS of $10.26 and revenue of $3.68 billion in the quarter were better than analysts’ estimates. Shares of Biogen rose about 3% in the pre-market trading session.
While Biogen lifted its EPS guidance for fiscal 2020, it lowered the revenue expectations.
The company lifted FY20 GAAP EPS outlook to a range of $32.00 and $34.00 from the prior guidance range of $29.50 to $31.50. Non-GAAP EPS is now expected to be between $34.00 and $36.00 versus a prior range of $31.50 to $33.50.
Revenue outlook for FY20 is cut down to a range of $13.8 billion to $14.2 billion from the prior expected range of $14.0 billion to $14.3 billion.
Visa Inc. (NYSE: V) reported first quarter 2023 earnings results today. Net revenues grew 12% year-over-year to $7.9 billion. GAAP net income rose 6% to $4.2 billion while EPS grew
Intel Corporation (NASDAQ: INTC) Thursday reported a decline in adjusted earnings and revenues for the fourth quarter. The semiconductor giant also provided guidance for the first quarter of 2023. Fourth-quarter
Shares of McCormick & Company Inc. (NYSE: MKC) were down over 5% on Thursday after the company missed expectations on its fourth quarter 2022 results and provided a lower-than-expected earnings